Selenium-Binding Protein 1 (SBP1) autoantibodies in ovarian disorders and ovarian cancer

Abstract

Infertility is a risk factor for ovarian cancer (OvCa). The goal was to determine if antibodies to Selenium Binding Protein 1 (SBP1), an autoantibody we identified in patients with premature ovarian failure (POF), occurs in both infertility and OvCa patients, and thus could be associated with preneoplasia. Anti-SBP1 was measured by immunoassay against recombinant SBP1, in sera from OvCa (n=41), infertility (n=92) and control (n=87) patients. Infertility causes were POF, unexplained, irregular ovulation or endometriosis. The percent of anti-SBP1 positive sera was higher in POF (p=0.02), irregular ovulation (p=0.001), unexplained causes (p=0.02), late (III–IV) stage OvCa (p=0.02) but was not significant in endometriosis, benign ovarian tumors/cysts, early stage (I–II) OvCa or uterine cancer compared to healthy controls. Anti-SBP1 was significantly higher in women with serous (p=0.04) but not non-serous (p=0.33) OvCa compared to controls. Also, we determined if anti-SBP1 was associated with CA125 or anti-p53, markers often studied in OvCa. Anti-p53 and CA125 were measured by established immunoassays. The ability of anti-SBP1 alone to discriminate infertility or OvCa from controls, or when combined with anti-p53 and CA125, to identify OvCa was evaluated by comparing the Area Under the Curve (AUC) in ROC analysis. Anti-SBP1 alone discriminated infertility (AUC=0.7; p=0.001) or OvCa (AUC=0.67; p=0.03) from controls. The sensitivity and specificity of OvCa identification was increased by combining CA125, anti-p53 and anti-SBP1 (AUC=0.96). Therefore, anti-SBP1 occurs in infertile women with POF, ovulatory disturbances or unexplained infertility and in serous OvCa. This suggests an autoimmune process is associated with development of serous OvCa.

Serum Anti-PDLIM1 Autoantibody as Diagnostic Marker in Ovarian Cancer

“…A study reported that a panel with four biomarkers [CA125, macrophage inhibitory factor (MIF), osteopontin (OPN), and anti-IL-8 autoantibodies] could identify 82.0% of OC with early stage compared to 65% with CA125 alone ( 35 ). It was demonstrated that the combination of CA125, anti-SBP1, and anti-TP53 greatly improved the sensitivity and specificity of OC identification with the AUC of 0.96 ( 36 ). From this study, the combination of anti-PDLIM1 AAb and CA125 could detect 79.2% patients with OC, which is statistically higher than when using CA125 or anti-PDLIM1 AAb alone.…”

The Increase of Circulating PD-1- and PD-L1-Expressing Lymphocytes in Endometriosis: Correlation with Clinical and Laboratory Parameters

“…Based on research on the interdependence of endometriosis and disorders of the immune system, a number of abnormalities in the immune system in patients with endometriosis was postulated. The impaired function of T cells, B cells, and NK cells, the increased levels of various proinflammatory cytokines and angiogenetic factors such as IL-6, IL-1, and TNF- α , and the production of autoantibodies have been proved [10–13].…”

Influence of reproductively significant autoantibodies on the quality of oocytes, obtained embryos and the chances of implantation in Assisted Reproductive Technologies cycles. Literature review

“…In a recent study, Yu-Rice et al found a significantly more frequent presence of anti-SBP1 antibodies in the sera of women with ovulatory disorders (50.0 %, p = 0.007), idiopathic infertility (24.3 %, p = 0.02) and premature ovarian failure (28.0 %, p = 0.02) relatively to the control group. Moreover, the same authors noted a more frequent occurrence of antibodies in serous ovarian tumors and suggested that anti-SBP-1 can be used as a predictor of ovarian cancer in the future [115]. This conclusion seems quite logical, given that in a number of experimental studies performed much earlier, the ability of SBP1 to suppress tumor growth was noted [116; 117].…”